PARIS--(BUSINESS WIRE)-- Abiomed (NASDAQ: ABMD) announces today that the Impella CP ® with SmartAssist technology, which is designed to improve patient outcomes with advanced algorithms and simplified ...

The Impella heart pump is a small pump that a healthcare professional can insert without surgery. It can help maintain blood flow in people who have CAD, are recovering from cardiogenic shock, or are ...

DANVERS, Mass.--(BUSINESS WIRE)-- The final results of the physician-led National Cardiogenic Shock Initiative (NCSI) Study demonstrate a 71% survival to discharge with greater than 90% native heart ...

ATLANTA -- Routine use of the Impella CP microaxial flow pump significantly improved survival in patients with infarct-related cardiogenic shock, the randomized DanGer Shock trial showed. In more than ...

LAS VEGAS--(BUSINESS WIRE)--Abiomed (NASDAQ:ABMD) announces that new data from the National Cardiogenic Shock Initiative Study (NCSI) on 171 consecutive AMI cardiogenic shock (AMICS) patients from 35 ...

TCT 69: Impella use for fulminant myocarditis in cardiogenic shock: Analysis of the Japan Registry for Percutaneous Ventricular Assist Device (J-PVAD) Receive the the latest news, research, and ...

Please provide your email address to receive an email when new articles are posted on . Abiomed is recalling specific Impella 5.5 left ventricular device systems due to product leakage. The FDA ...

Investigators for the DanGer trial are spreading the word on their plans to test Impella—notably, in a randomized, controlled fashion—in patients with acute MI complicated by cardiogenic shock (AMICS) ...

DANVERS, Mass.--(BUSINESS WIRE)--Abiomed (NASDAQ: ABMD) announces the United States Food and Drug Administration (FDA) has approved the company's investigational device exemption application to start ...

The U.S. FDA posted notice of a medical device correction of Abiomed Inc.'s Impella series of left-side blood pumps because of the risk of perforation of the left ventricle during device placement.